SGLT 2 INHIBITORS | Latest News RSS feed


SGLT2 Inhibitors and Amputations in Diabetes: Still Unclear

Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes may be associated with an increased risk for below-the-knee amputations compared with some oral diabetes t... read more

Mixed Data on SGLT-2 Inhibitors' Amputation Risk

Be aware that sodium-glucose cotransporter 2 (SGLT-2) inhibitors may be tied to an increased risk for lower extremity amputations compared with other type 2 diabetes therapies, based on a retrospectiv... read more

Association between SGLT-2 inhibitors and lower extremity amputation among patients with type 2 diabetes

New users of sodium-glucose cotransporter 2 (SGLT-2) inhibitors may have a greater risk of amputation compared with some oral treatments for type 2 diabetes, according to new research. The retrospecti... read more

Looking for another news?

SGLT-2 inhibitors may increase risk for amputation in type 2 diabetes

New users of sodium-glucose cotransporter 2 inhibitors may be more likely to undergo a lower extremity amputation when compared with users of other treatments for type 2 diabetes, such as sulfonylurea... read more

SGLT2 inhibitors continue to be linked with amputation risk in type 2 diabetes

Research has again linked the drug class sodium-glucose co-transporter-2 (SGLT2) inhibitors to an increased risk of amputation in people with type 2 diabetes. SGLT2 inhibitors help to lower the blood ... read more

Diabetes patients on SGLT-2 inhibitors at increased risk for amputation

Researchers who studied 953,906 patients with type 2 diabetes and a mean age of 51.8 found a higher risk of lower extremity amputation among new users of SGLT-2 inhibitors, compared with new users of ... read more

SGLT-2 Inhibitors: What You and Your Patient Should Know to Prevent DKA

It is now well known or should be that SGLT-2s increase the risk for diabetes ketoacidosis (DKA) in people who have type 2 diabetes. Man, 67 years of age, had been on GLP-1, SGLT-2, and metformin for ... read more

New diabetes drug linked to rare but serious side effect

In a recent study from Brigham and Women’s Hospital, researchers find that a new drug for type 2 diabetes, known as SGLT2 inhibitors, may increase the risk of rare but serious complication called diab... read more

Sirona Biochem Announces CFDA Approval of SGLT2 Inhibitor for Phase I Clinical Trial

July 12, 2018 08:00 ET | Source: Sirona Biochem Corp. VANCOUVER, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V:SBM) (FSE:ZSB) (the “Company”) announced today that par... read more

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

INDIANAPOLIS, Feb. 26, 2018 /PRNewswire/ -- Trulicity ® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sod... read more

Research examines efficacy of SGLT-2 inhibitor as 2nd-line diabetes therapy

Researchers used a cohort of 9,097 adults with type 2 diabetes and found that more than one-third of those who took SGLT-2 inhibitors as a second-line therapy to metformin experienced an HbA1C reducti... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us